LB Bohle – 10.06.2025
Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Stoelzle – 15th May 2025

Returning to Basics of siRNA Design to Fulfil Therapeutic Potential

The recent FDA approval of siRNA therapeutics has re-energised the RNA interference (RNAi) field. The discovery of RNAi mediated silencing in mammalian cells and parallel availability of the whole human genome sequence allowed for creation of research tools to study gene function using siRNA. However, due to challenges in siRNA delivery and pharmacokinetics, its potential as a therapeutic was not realised until the FDA approval of the siRNA therapeutics ONPATTRO® (patisiran) and GIVLAARI® (givosiran) in 2018 and 2019, respectively. Annaleen Vermeulen and Amanda Haas at Horizon Discovery discuss how the success of these therapeutics builds on almost two decades of siRNA design and encourages the field to pursue additional gene targets for therapeutic intervention.

 

Scott Pharma – 25.03.2025
Bespak – 21.05.2025
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
Nipro – 09.06.2025
L.B. Bohle – 08.04.2025
Drug Discovery 2025, ELRIG – 04.07.2025